Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (SE:COMBI)
:COMBI
Top Page
CombiGene AB
(Frankfurt:COMBI)
49Neutral
CombiGene AB (COMBI) vs. S&P 500 (SPY)
Market Cap
kr50.10M
Dividend YieldN/A
Average Volume (3M)15.52K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth-94.12%
EPS Growth-25.83%
CountrySE
Employees11
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.27
Shares Outstanding19,801,197
10 Day Avg. Volume8,157
30 Day Avg. Volume15,523
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CombiGene AB Business Overview & Revenue Model
Company DescriptionCombiGene AB (COMBI) is a biotechnology company focused on the development of innovative gene therapy solutions to treat severe life-altering diseases. Operating within the healthcare sector, CombiGene specializes in leveraging cutting-edge genetic technologies to create therapies that address unmet medical needs. The company's core products are centered around gene therapy treatments, particularly in the areas of neurological disorders and metabolic diseases.
How the Company Makes MoneyCombiGene makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue by partnering with larger pharmaceutical companies for the co-development, licensing, and distribution of its therapies. These partnerships often include upfront payments, milestone payments, and royalties on sales. Additionally, CombiGene may secure funding from grants and research collaborations with academic institutions and research organizations, which support the advancement of its therapeutic programs.
CombiGene AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 326.00K | 5.54M | 26.70M | 84.04M | 10.83M | Gross Profit |
| 326.00K | -21.29M | -19.20M | 15.16M | 8.33M | EBIT |
| -47.22M | -36.31M | -6.95M | 20.96M | -28.16M | EBITDA |
| -34.22M | -35.98M | -5.86M | 23.56M | -25.66M | Net Income Common Stockholders |
| -44.88M | -35.67M | -5.37M | 20.96M | -30.77M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 73.75M | 101.44M | 131.78M | 136.74M | 48.90M | Total Assets |
| 75.88M | 120.61M | 158.22M | 166.22M | 79.41M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -73.75M | -101.44M | -131.78M | -136.74M | -48.90M | Total Liabilities |
| 4.30M | 4.16M | 6.10M | 7.94M | 7.98M | Stockholders Equity |
| 71.58M | 116.46M | 152.12M | 158.28M | 71.43M |
| Cash Flow | Free Cash Flow | |||
| -29.95M | -30.67M | -16.67M | 21.97M | -38.45M | Operating Cash Flow |
| -29.95M | -30.56M | -16.67M | 22.11M | -38.35M | Investing Cash Flow |
| -81.00K | -988.90K | 0.00 | -147.73K | -3.21M | Financing Cash Flow |
| 0.00 | 0.00 | 0.00 | 65.88M | 75.29M |
CombiGene AB Technical Analysis
Neutral
2.35
Price Trends
2.42
Negative
2.44
Negative
2.53
Negative
Market Momentum
>-0.01
Negative
51.18
Neutral
25.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:COMBI, the sentiment is Neutral. The current price of 2.35 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.42, and below the 200-day MA of 2.53, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.18 is Neutral, neither overbought nor oversold. The STOCH value of 25.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:COMBI.
CombiGene AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
49 Neutral | kr50.10M | ― | -47.01% | ― | -94.12% | -25.83% | |
44 Neutral | €77.76M | ― | -96.58% | ― | 30.02% | -3985.71% | |
41 Neutral | kr54.47M | ― | -59.73% | ― | ― | 45.38% | |
40 Underperform | kr51.84M | ― | -55.51% | ― | -57.26% | 72.71% | |
36 Underperform | kr71.73M | ― | -85.93% | ― | 58.72% | 70.69% | |
35 Underperform | kr46.00M | ― | -152.99% | ― | ― | 58.36% |
* Healthcare Sector Average
Performance Comparison
SE:COMBI
CombiGene AB
2.41
-1.36
-36.07%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
19.50
-74.16
-79.18%
SE:MODTX
Modus Therapeutics Holding AB
1.28
0.31
32.23%
SE:ONCOZ
OncoZenge AB
4.65
0.76
19.38%
SE:SPAGO
Spago Nanomedical AB
0.22
-0.14
-39.17%
SE:SPRINT
Sprint Bioscience AB
0.66
-0.61
-47.95%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.